Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes.
Level 5 - mechanism / opinion, no new human data
Narrative review of biochemical pathways and mechanistic rationales without systematic review or primary clinical trial data.
PubMed 29634344 · doi:10.1089/ars.2017.7269
What was done
This narrative review synthesized biochemical mechanisms governing NAD+ homeostasis, causes of NAD+ depletion (including PARP activation from DNA damage and CD38 activation from inflammation), and the roles of key NAD+ precursors (nicotinamide, nicotinic acid, nicotinamide riboside, and nicotinamide mononucleotide) in degenerative disease models and physiological aging.
What was found
The abstract provides conceptual and mechanistic summaries rather than quantitative metrics or trial effect sizes. It details that enhancing NAD+ levels supports sirtuin activity and reduces oxidative cell damage in catabolic tissues such as the brain, while highlighting that different precursors vary in their synthesis efficiency depending on their entry point in anabolic pathways.
Why it matters
It outlines the biological rationale for using specific NAD+ intermediate precursors as potential therapeutic interventions to preserve cellular resilience in age-related degenerative conditions.
Limits
As a non-systematic narrative review, it reports no original empirical data, quantitative pooling, or clinical outcome metrics. Specific human trial designs, sample characteristics, dosages, and safety parameters are not detailed in the abstract.
Cited by
- supports NAD levels decline with age and are reduced in individuals with chronic degenerative conditions.